Prinomastat is an inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, MMP-9, MMP-13, and MMP-14 (IC50s = 0.05, 0.3, 0.26, 0.03, and 0.33 nM, respectively).1 It is selective for these MMPs over MMP-1 and MMP-7 (IC50s = 8.3 and 54 nM, respectively). Prinomastat (50 mg/kg) reduces tumor growth and inhibits the formation of lung metastases in a murine Lewis lung carcinoma model. It also reduces the incidence of kidney, but not brain, metastasis and tumor microvessel density in an NCI H460 lung cancer orthotopic mouse model when administered at a dose of 100 mg/kg.2 Prinomastat reduces bronchoalveolar lavage fluid (BALF) levels of TNF-α and pulmonary edema in a rat model of ventilator-induced lung injury.3
1.Scatena, R.Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseasesExpert Opin. Investig. Drugs9(9)2159-2165(2000) 2.Liu, J., Tsao, M.S., Pagura, M., et al.Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer modelLung Cancer42(3)335-344(2003) 3.Foda, H.D., Rollo, E.E., Drews, M., et al.Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: Attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340)Am. J. Respir. Cell Mol. Biol.25(6)717-724(2001)